Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $88.3M | $103M | $207M | $205M | $122M | $97.1M | $86.2M | $79.2M | $67.6M | $65.3M |
| Revenue growth | — | 16.5% | 101.0% | -0.7% | -40.3% | -20.7% | -11.2% | -8.1% | -14.6% | -3.4% |
| Operating income | $30.8M | $24.6M | $88.3M | $36.7M | -$41.6M | -$110M | -$124M | -$137M | -$122M | -$85.3M |
| Operating margin | 34.9% | 23.9% | 42.7% | 17.9% | -34.0% | -112.9% | -143.7% | -173.2% | -179.9% | -130.7% |
| Net income | $21.7M | $17.7M | $72.0M | $46.4M | -$36.2M | -$79.0M | -$122M | -$134M | -$116M | -$81.9M |
| Net margin | 24.5% | 17.2% | 34.8% | 22.6% | -29.5% | -81.4% | -141.3% | -169.0% | -171.6% | -125.4% |
| EPS (diluted) | $1.13 | $0.91 | $3.48 | $2.21 | -$1.81 | -$3.92 | -$5.91 | -$6.38 | -$5.48 | -$3.84 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $35.8M | $52.7M | $29.2M | $71.4M | $7.09M | -$70.0M | -$84.8M | -$103M | -$78.8M | -$19.3M |
| Capital expenditures | $4.74M | $2.51M | $2.98M | $5.42M | $1.45M | $750K | $2.13M | $9.06M | $17.9M | $12.9M |
| Free cash flow | $31.1M | $50.1M | $26.2M | $66.0M | $5.64M | -$70.7M | -$86.9M | -$112M | -$96.7M | -$32.2M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $16.6M | $65.7M | $63.9M | $51.2M | $87.1M | $57.2M | $44.0M | $85.4M | $37.2M | $32.3M |
| Total assets | $281M | $327M | $414M | $490M | $486M | $439M | $375M | $462M | $377M | $281M |
| Total liabilities | $11.3M | $25.0M | $20.5M | $27.3M | $30.6M | $39.4M | $54.1M | $246M | $248M | $216M |
| Shareholders' equity | $270M | $302M | $394M | $462M | $456M | $399M | $321M | $217M | $129M | $64.7M |
| Retained earnings | $27.6M | $45.4M | $117M | $164M | $128M | $48.6M | -$73.2M | -$207M | -$323M | -$405M |
| Shares (wtd avg diluted) | 19.2M | 19.4M | 20.6M | 21.0M | 19.9B | 20.2B | 20.6B | 21.0B | 21.2B | 21.3B |
Every figure is extracted from ENANTA PHARMACEUTICALS INC’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.